Bordetella parapertussis isolates not expressing pertactin circulating in France

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
Valérie BouchezN Guiso

Abstract

Surprisingly, most Bordetella parapertussis isolates collected in France since 2007 do not express pertactin, owing to mutations in the structural gene encoding this protein. We used a 454 pyrosequencing strategy to study and compare the genetics of two B. parapertussis isolates (one expressing pertactin and one not expressing pertactin) and the reference strain. No region of difference was detected between the genomes of the two isolates and the genome of the reference strain. No increase in repeated sequences between both isolates was found, and there were very few sequence differences. Using cellular and animal models, we found no substantial difference between the pathogenicity of these B. parapertussis isolates, which is consistent with clinical data. The emergence of these isolates, indicating that pertactin expression is not essential for virulence for B. parapertussis, is discussed.

References

Mar 1, 1990·The Journal of Infectious Diseases·P Novotny
Aug 26, 1998·JAMA : the Journal of the American Medical Association·Q HeJ Mertsola
Aug 25, 2001·Journal of Endotoxin Research·M CaroffD Karibian
Jun 18, 2002·Infection and Immunity·Ulrich HeiningerEric T Harvill
May 29, 2004·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Letowska, W Hryniewicz
Oct 16, 2004·Expert Review of Anti-infective Therapy·Mineo Watanabe, Masaaki Nagai
Oct 17, 2006·Journal of Evolutionary Biology·D A DiavatopoulosF R Mooi
Feb 21, 2008·Infection and Immunity·Elizabeth M GoebelEric T Harvill

❮ Previous
Next ❯

Citations

Aug 14, 2012·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A TizolovaS Guillot
Oct 10, 2013·The Journal of Infection·Nicole Guiso
Apr 30, 2013·Emerging Infectious Diseases·Hélène Bodilis, Nicole Guiso
Feb 15, 2013·Epidemiology and Infection·F R MooiH E De Melker
Aug 6, 2015·Pathogens and Disease·Valérie Bouchez, Nicole Guiso
Jul 8, 2015·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Olivier Restif, Andrea L Graham
Nov 19, 2011·FEMS Immunology and Medical Microbiology·Habib BokhariFrits R Mooi
Oct 11, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stacey W MartinThomas A Clark
Jun 22, 2012·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·N HegerleN Guiso
Apr 24, 2014·Therapeutic Advances in Vaccines·Nicole Guiso
Jun 24, 2014·Expert Review of Vaccines·Nicolas Hegerle, Nicole Guiso
Oct 16, 2019·Journal of Medical Microbiology·Kazunari KamachiMineo Watanabe
Jul 19, 2014·Expert Review of Vaccines·Nicole Guiso, Nicolas Hegerle
Aug 5, 2014·Expert Review of Vaccines·Jan T Poolman
May 26, 2016·Expert Review of Anti-infective Therapy·Nicole Guiso, Carl Heinz Wirsing von König
Sep 1, 2017·Microbiology and Immunology·Jimena Alvarez HayesMaria Eugenia Rodriguez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.